Kura Oncology

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Kura Oncology reports Q4 loss, highlights ziftomenib's AML potential

Kura Oncology's Q4 2022 performance reflects increased R&D expenses and a net loss, offset by a strong cash position supporting operations.
The company's focus on ziftomenib's positive trial data, combination studies, and patient-centric strategies positions it for future growth.
Challenges lie in managing treatment complexities, strategic resource allocation, and balancing commercial value with patient benefit.
Opportunities include upcoming milestones, exploration of combination therapies, and regulatory advancements for ziftomenib.

Kura Oncology sees positive results with ziftomenib in Q1

Kura Oncology's Q1 2023 earnings call highlighted the promising performance of ziftomenib in AML patients, supported by strong Phase 1 trial data and strategic plans for combination studies.
While facing challenges in competitive differentiation and trial execution, the company's financial stability and focus on methodical drug development underscore its long-term potential.
Opportunities lie in achieving key milestones, exploring new therapeutic applications, and leveraging a competitive edge in the menin inhibitor space for future growth and success.

Kura Oncology reports Q2 loss, sees growth in clinical trials

Kura Oncology's Q2 2023 performance reflects increased expenses but promising clinical outcomes, with strong enrollment and positive data in key trials.
Strategic strengths lie in combination studies, diversified indications, and positive trial results, positioning the company for future growth and market expansion.
Challenges include resource constraints, research prioritization, and evolving resistance issues, necessitating adaptive strategies and efficient resource management.
Opportunities for Kura Oncology include collaborations, out-licensing, and program expansions, offering avenues for operational efficiency and revenue growth.

Kura Oncology's ziftomenib shows promise in acute leukemias, financials stable

Kura Oncology's Q3 performance reflects increased expenses but maintains a strong financial position.
The company's lead drug candidate, ziftomenib, shows promise in acute leukemias, with positive response rates.
Strategic strengths include progress with menin inhibitors, successful combination approaches, and clinical collaborations.
Challenges lie in meeting enrollment timelines, addressing efficacy questions, and balancing program investments.

Kura Oncology reports promising clinical data and financial stability

Kura Oncology's Q4 2023 performance showcased positive clinical data and financial stability, positioning the company well for future growth.
While challenges in data interpretation and differentiation exist, opportunities in milestone achievements and patient-focused therapies are on the horizon.
The company's strategic focus on early therapy lines and combinability of menin inhibitors highlight its strengths in the competitive market landscape.

Kura Oncology reports promising results for ziftomenib in Q1

Kura Oncology's Q1 2024 performance reflects increased R&D expenses and promising results for ziftomenib.
Strengths lie in FDA support, encouraging safety profiles, and ongoing combo dose escalation trials.
Challenges include patient characteristics impacting therapy duration and strategic resource allocation.
Opportunities include upcoming milestones, solid tumor data disclosure, and competitor monitoring for market insights.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Event to follow presentation of preliminary clinical data for menin inhibitor KO-539 at ASH Event to follow presentation of preliminary clinical data for menin inhibitor KO-539 at ASH

Kura Oncology to Host Virtual Investor Event on December 5, 2020

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q3 2020 Results - Earnings Call Transcript

SAN DIEGO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report third quarter 2020 financial results before the open of U.S. financial markets on Thursday, November 5, 2020. Kura's management will host a webcast and conference call at 8 a.m. ET / 5 a.m. PT that day to discuss the financial results and provide a corporate update.

Kura Oncology to Report Third Quarter 2020 Financial Results

– Preclinical data support potential to expand therapeutic utility of tipifarnib to HRAS/PI3K dependent tumors representing up to 50% of HNSCC –

Kura Oncology Reports Preclinical Results Showing Antitumor Activity of Tipifarnib in Combination with PI3Kα Inhibitor in Head and Neck Squamous Cell Carcinoma

– First clinical data from the KOMET-001 study to be presented on December 5, 2020 – – First clinical data from the KOMET-001 study to be presented on December 5, 2020 –

Kura Oncology Announces Preliminary Data for Menin Inhibitor KO-539 Accepted for Oral Presentation at ASH

Kura Oncology shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.
The post Kura Oncology Clears Key Benchmark, Hitting 90-Plus RS Rating appeared first on Investor's Business Daily.

Kura Oncology Clears Key Benchmark, Hitting 90-Plus RS Rating

Kura Oncology (KURA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Kura Oncology (KURA) Looks Good: Stock Adds 6.8% in Session

SAN DIEGO, Aug.  25, 2020  (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced the appointment of Stephen Dale, M.D., as Chief Medical Officer. Dr. Dale joins Kura most recently from Kyowa Kirin, where he served as Senior Vice President and Global Head of Medical Science with a primary focus in oncology.

Kura Oncology Appoints Dr. Stephen Dale as Chief Medical Officer

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q2 2020 Results - Earnings Call Transcript

SAN DIEGO, Aug.  04, 2020  (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation at the 2020 Wedbush PacGrow Healthcare Virtual Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to present an overview of the company on Tuesday, August 11, 2020 at 2:20 p.m. ET / 11:20 a.m. PT. The virtual conference will be held from August 11-12, 2020.

Kura Oncology to Present at Wedbush PacGrow Healthcare Virtual Conference

SAN DIEGO, July  30, 2020  (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report second quarter 2020 financial results after the close of U.S. financial markets on Thursday, August 6, 2020. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

Kura Oncology to Report Second Quarter 2020 Financial Results

SAN DIEGO, June  11, 2020  (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the JMP Securities Hematology & Oncology Forum (Virtual). Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat on Thursday, June 18, 2020 at 10:40 a.m. ET / 7:40 a.m. PT. The virtual forum will be held from June 18-19, 2020.

Kura Oncology to Participate in JMP Securities Hematology & Oncology Forum

– Oral presentation to highlight clinical data for tipifarnib in HRAS mutant solid tumors, including overall survival data in head and neck squamous cell carcinoma – – Oral presentation to highlight clinical data for tipifarnib in HRAS mutant solid tumors, including overall survival data in head and neck squamous cell carcinoma –

Kura Oncology Announces Three Abstracts Accepted for Presentation at ASCO20 Virtual Scientific Program

SAN DIEGO, May  06, 2020  (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the pricing of an underwritten public offering of 9,100,000 shares of its common stock at a price to the public of $13.75 per share. The gross proceeds to Kura from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Kura, are expected to be approximately $125.1 million. In addition, Kura has granted the underwriters a 30-day option to purchase up to an additional 1,365,000 shares of common stock. The offering is expected to close on or about May 8, 2020, subject to customary closing conditions.

Kura Oncology Announces Pricing of $125 Million Public Offering of Common Stock

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q1 2020 Results - Earnings Call Transcript

Kura Oncology is riding the coattails of another clinical-stage biopharmaceutical company.

Why Kura Oncology Is Skyrocketing Today

– Second Fast Track designation for tipifarnib further highlights potential for tipifarnib to address unmet need for patients –

Kura Oncology Receives Fast Track Designation for Tipifarnib in T-Cell Lymphomas

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q4 2019 Results - Earnings Call Transcript

– Dr. Antonio Gualberto to step down after enabling multiple registrational strategies for tipifarnib, positioning program for success –

Kura Oncology Announces Transition of Chief Medical Officer

Company strengthens leadership team to support pre-commercial efforts and launch optimization Company strengthens leadership team to support pre-commercial efforts and launch optimization

Kura Oncology Appoints Kirsten Flowers as Chief Commercial Officer

– Fast Track designation highlights potential for tipifarnib to address unmet need for patients with HRAS mutant HNSCC –

Kura Oncology Receives Fast Track Designation for Tipifarnib in HRAS Mutant HNSCC and Provides Enrollment Guidance for AIM-HN Trial

– Tipifarnib demonstrates robust and durable activity as a monotherapy in advanced AITL, an aggressive form of T-cell lymphoma –

Kura Oncology Reports Clinical and Regulatory Updates for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma

Kura Oncology Should Be On Your Radar With Upcoming Presentation For Cancer Study

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q3 2019 Results - Earnings Call Transcript

– Former Biogen senior counsel brings more than 20 years of combined in-house and law firm experience – – Former Biogen senior counsel brings more than 20 years of combined in-house and law firm experience –

News for Kura Oncology Stock (KURA)